In a previous study, ET patients with CALR mutations appeared to have lower hemoglobin levels and white blood cell counts, higher platelet counts, a lower risk of thrombosis, and a much higher rate of survival and fibrosis progression than ET patients with JAK2 mutation [9, 10]. Here, CALR is linked to essential thrombocythemia.